(For treatment side effects and complications only)
ABVD + Rituximab Nodular Lymphocyte Prominent Hodgkin’s Lymphoma and Nodular Lymphocyte Prominent B-Cell Lymphoma V1.0
Acalabrutinib (monotherapy) Chronic Lymphocytic Leukaemia Protocol V1.1
BeGEV Relapsed or Refractory Hodgkin Lymphoma v1.0
BCHP (Brentuximab, Cyclophosphamide, Doxorubicin) Systemic Anaplastic Large Cell Lymphoma V2.0
Brentuximab Hodgkin’s Lymphoma - Systemic Anaplastic Large Cell Lymphoma and CD30+ Cutaneous T-cell Lymphoma Protocol V2.0
CHOP + / - Rituximab Non-Hodgkin’s Lymphoma Protocol V2.0
CVP + / - Rituximab Non-Hodgkin’s Lymphoma Protocol V2.0
Dose Adjusted (DA) EPOCH +/- Rituximab High Grade Non-Hodgkin Lymphoma V1.0
DDGP - Dexamethasone, Cisplatin, Gemcitabine and Peg-aspargase v1.0
DHAP +- Rituximab Relapsed or Refractory Lymphoma V1.0
Escalated BEACOPDac High Grade Hodgkin Lymphoma V1.0
Escalated BEACOPP Hodgkin’s Lymphoma Protocol V1.1
ESHAP +- Rituximab Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma V1.0
GCVP +/- Rituximab Non Hodgkins Lymphoma V1.0
GDP +- Rituximab Relapsed or Refractory Hodgkin's or Non-Hodgkin's Lymphoma V2.0
High Dose Methotrexate CNS NHL Prophylaxis V1.0
High Dose Methotrexate Overview Leukaemia Lymphoma V2.0
Ibrutinib Chronic Lymphocytic Leukaemia & Lymphoma Protocol V2.0
Ibrutinib and Venetoclax Chronic Lymphocytic Leukaemia (CLL) V1.0
Imatinib v2.0
ICE +- Rituximab (INPATIENT) Relapsed or Refractory Lymphoma V1.0
ICE +- Rituximab (OUTPATIENT) Relapsed or Refractory Lymphoma V1.0
IGEV +- Rituximab Relapsed or Refractory Hodgkin's or Non-Hodgkin's Lymphoma V1.0
IVE +- Rituximab Relapsed or Refractory Lymphoma V1.0
Lyaspmedex PEG Asparaginase, Methotrexate, Dexamethasone V2.0
MATRIX Primary CNS Lymphoma V2.1
Mini-CHOP +or - Rituximab Non-Hodgkin's Lymphoma V2.0
Mogamulizumab Mycosis Fungoides Sezary Syndrome V1.0
Nivolumab Relapsed Refractory Hodgkin’s Lymphoma V2.0
Nordic (R-maxi-CHOP alternating with R- HD cytarabine) Mantle Cell Lymphoma Protocol V2.0
Obinutuzumab & Bendamustine - Previously Untreated & Relapsed or Refractory Follicular Lymphoma Protocol V1.0
Obinutuzumab & CHOP - Previously Untreated Follicular Lymphoma Protocol V1.0
Obinutuzumab & CVP - Previously Untreated Follicular Lymphoma Protocol V1.0
Obinutuzumab Maintenance - Follicular Lymphoma Protocol V1.0
Obinutuzumab and Venetoclax Chronic Lymphocytic Leukaemia Protocol V1.0
Pembrolizumab Relapsed Refractory Hodgkin's Lymphoma V2.0
Polatuzumab Vedotin, Rituximab and Bendamustine Diffuse Large B Cell Lymphoma (DLBCL) V2.0
R-BAC Relapsed-Refractory Non-Hodgkin’s Lymphoma Protocol V2.0
R-CODOX-M / R-IVAC Burkitt Lymphoma / DLBCL with adverse features V1.0
Rituximab Administration Guideline V1.0
Rituximab Single Agent v 2.0
Rituxumab-Bendamustine for First Line CLLL and Low Grade NHL v2.0
Rituximab-Chlorambucil Chronic Lymphocytic Leukaemia Protocol V2.0
Rituximab, Fludarabine and Cyclophosphamide (R-FC) Chronic Lymphocytic Leukaemia Protocol V1.0
Rituximab-Lenalidomide (R2) Relapsed-Refractory NHL Compassionate Use v2.0
Rituximab-Lenaldomide (R2) Relapse Follicular Lymphoma v 2.0
Rituximab-Polatuzumab-CHP Diffuse Large B Cell Lymphoma (DLBCL) V2.0
RMP (Rituximab, Methotrexate, Procarbazine) Primary CNS Lymphoma V3.0
R-MAA - Rituximab, Methotrexate & Cytarabine Primary CNS Lymphoma V1.0
Maintenance Subcutaneous (sc) Rituximab B-Cell Lymphomas V2.0
Venetoclax +/- Rituximab Chronic Lymphocytic Leukaemia Protocol V3.0
Vinblastine monotherapy Relapsed / Refractory T Cell Lymphomas V1.0
Zanubrutinib Waldenstrom’s Macroglobulinaemia V1.0